Solid Biosciences Q2 net loss widens to $39.5 mln

Solid Biosciences

12/08/2025 21:36

Overview

Solid Biosciences reports Q2 2025 net loss of $39.5 mln, up from Q2 2024

R&D expenses rose due to increased costs for SGT-003 program

Company ended Q2 2025 with $268.1 mln in cash, runway into H1 2027

Outlook

Company to discuss SGT-003 regulatory pathways with FDA in Q4 2025

Company expects SGT-212 Phase 1b trial initiation in Q4 2025

SGT-501 Phase 1b trial initiation expected in Q4 2025

Solid anticipates cash runway into H1 2027

Result Drivers

INCREASED R&D EXPENSES - R&D expenses rose due to manufacturing, regulatory, and clinical costs for SGT-003

CASH POSITION - Company ended Q2 with $268.1 mln in cash

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.42
Q2 Net Income
-$39.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, about 62% above its August 11 closing price of $6.08

Press Release: ID:nGNX7YmgF5

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)